Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Transplant Infectious Disease
What is your approach to management of mycoplasma pneumonia in heavily immunosuppressed patients?
Related Questions
Would you recommend treating asymptomatic bacteriuria in a kidney transplant patient who has a ureteral stent in place?
What factors influence your decision to initiate antifungal treatment in asymptomatic lung transplant recipients colonized with Aspergillus?
How do you approach using fecal microbiota therapy for recurrent Clostridioides difficile infection in immunocompromised patients?
How should the timing of RSV vaccination be managed for patients who undergo stem cell transplant during periods of high community transmission?
What drug and specific dosing would you use for secondary pneumocystis prophylaxis in a patient with renal transplant, documented TMP-SMX allergy, and normal G6PD testing, who was diagnosed with moderate PJP and improved on clindamycin/primaquine and steroids?
When do you consider extended courses of oseltamivir in immunocompromised patients?
How has your approach to managing asymptomatic bacteriuria in kidney transplant patients changed in light of a recent meta-analysis showing no significant differences in pyelonephritis, symptomatic UTI, or graft loss between patients treated with antibiotics and those who were not treated?
How do you manage increasing EBV viremia of 15,000 copies in a seropositive heart transplant recipient with transplant performed 15 years ago in a patient who is otherwise asymptomatic?
Do you manage antibacterials for enterococcal bacteremia differently in patients with severe immunosuppression?
Do you routinely discuss the risks of home composting with immunocompromised patients?
